Skip to main content

Table 1 Relationship between syndecan-1 immunoreactivity and clinicopathological characteristics

From: Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: An immunohistochemical study of clinically annotated tumors

 

Syndecan-1 staining (percentage of tumors in brackets)

 

0

1+

2+

3+

 
 

n = 38 (29%)

n = 27 (21%)

n = 49 (37%)

n = 17 (13%)

p

Variable

     

Age

    

0.651

   <65 yrs

16 (42.1)

12 (44.4)

17 (34.7)

6 (35.3)

 

   ≥ 65 yrs

22 (57.9)

15 (55.6)

32 (65.3)

11 (64.7)

 

Gender

    

0.042*

   Male

24 (63.2)

22 (81.5)

23 (46.9)

10 (58.8)

 

   Female

14 (36.8)

5 (18.5)

26 (53.1)

7 (41.2)

 

Stage

    

0.045*

   I/II

14 (36.8)

13 (48.1)

33 (67.3)

9 (52.9)

 

   III/IV

24 (63.2)

14 (51.9)

16 (32.7)

8 (47.1)

 

Lymph node metastasis

    

0.017*

   negative

16 (42.1)

14 (51.9)

36 (73.5)

12 (70.6)

 

   positive

22 (57.9)

13 (48.1)

13 (26.5)

5 (29.4)

 

Location

    

0.380

   Proximal

13 (34.2)

9 (33.3)

13 (26.5)

2 (11.8)

 

   Distal

25 (65.8)

18 (66.7)

36 (73.5)

15 (88.2)

Â